Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Compassionate Administration of ZVS101e for Extended Treatment
NCT07307469Enrolling by invitation
- Sponsor
- CHIGENOVO
- Start
- Jul 2026
- Primary completion
- Jan 2027
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 1
01
Overview
Open-label, single-arm trial of ZVS101e in Bietti crystalline dystrophy (BCD), sponsored by CHIGENOVO. Primary endpoint: Adverse Events at 4 weeks. Started Jul 2026; status: enrolling by invitation.
02
Drugs
ZVS101e
03
Conditions
Bietti crystalline dystrophy (BCD)
Beyond the preview
Go deeper on NCT07307469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07307469.